BREAKING

Victoria’s Secret (VSCO) Reports Q4 Adj. Earnings of $2.77/Share, up 6.5% 42 minutes ago Algonquin Reports Q4FY25 Earnings Rebound on Utility Growth 3 hours ago Myers Industries (MYE) Q4 Adjusted EPS Surges 63% to $0.31 on Margin Expansion 3 hours ago Embraer backlog hits record $31.6B as deliveries surge in Q4FY25 3 hours ago Capital Clean Energy Carriers (CCEC) Reports Q4 EPS of $0.48 on $98.3M Revenue 3 hours ago Genesco Q4 FY26 Results Show Strong Nine Percent Comp Growth 3 hours ago Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales 3 hours ago Autohome (ATHM) Q4 Earnings Meet Estimates at $0.09 EPS Despite Revenue Plunge to $209M 4 hours ago Global Ship Lease (GSL) Q4 Adjusted EPS Drops 9 % to $2.32, EBITDA Hits $124.7M 4 hours ago LXRX Reports Mixed Q4 Results: Loss Improves to $0.04 Per Share But Revenue Crashes 79% YoY 5 hours ago Victoria’s Secret (VSCO) Reports Q4 Adj. Earnings of $2.77/Share, up 6.5% 42 minutes ago Algonquin Reports Q4FY25 Earnings Rebound on Utility Growth 3 hours ago Myers Industries (MYE) Q4 Adjusted EPS Surges 63% to $0.31 on Margin Expansion 3 hours ago Embraer backlog hits record $31.6B as deliveries surge in Q4FY25 3 hours ago Capital Clean Energy Carriers (CCEC) Reports Q4 EPS of $0.48 on $98.3M Revenue 3 hours ago Genesco Q4 FY26 Results Show Strong Nine Percent Comp Growth 3 hours ago Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales 3 hours ago Autohome (ATHM) Q4 Earnings Meet Estimates at $0.09 EPS Despite Revenue Plunge to $209M 4 hours ago Global Ship Lease (GSL) Q4 Adjusted EPS Drops 9 % to $2.32, EBITDA Hits $124.7M 4 hours ago LXRX Reports Mixed Q4 Results: Loss Improves to $0.04 Per Share But Revenue Crashes 79% YoY 5 hours ago

ADVERTISEMENT

Breaking News

Tango Therapeutics (TNGX) Q4 Loss Narrows to $0.29/Share vs $0.33 Estimate; Shares Surge 23%

Tango Therapeutics posts narrower-than-expected Q4 loss of $0.29/share vs $0.33 estimate; shares jump 23% on the biotech's results.

$TNGX March 6, 2026 2 min read

NYSE

$TNGX · Earnings

“
Tango Therapeutics posts narrower-than-expected Q4 loss of $0.29/share vs $0.33 estimate; shares jump 23% on the biotech's results.
vishnu · March 6, 2026

Loss narrows modestly. Tango Therapeutics, Inc. (NASDAQ: TNGX) reported a loss of $0.29 per share for Q4 2025, narrower than the consensus estimate of a $0.33 loss. Shares surged 22.9% following the report, adding roughly $370 million in market value to reach a $2.05 billion market cap. Trading volume spiked to 9.8 million shares, well above typical levels for the biotechnology company.

Revenue data not disclosed. The company did not report quarterly revenue figures in its Q4 2025 earnings release. For early-stage biotechnology firms like Tango, which focus on drug development rather than commercialized products, revenue is often minimal or absent during the research phase. The market’s strong positive reaction suggests investors are focused on pipeline progress and cash runway rather than top-line growth at this stage of the company’s development.

Earnings Per Share

$-0.29

vs $-0.33 est. (narrower loss, 11.8%)

Revenue

—

estimate N/A

What to Watch: Monitor Tango’s next clinical trial readout or regulatory milestone announcement, which will determine whether the market’s optimism following this earnings beat translates into sustained valuation support. Cash burn rate and runway guidance in the full earnings call transcript will signal how long the current balance sheet supports operations without additional financing.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

ADVERTISEMENT

Tags: #TNGX